William Blair analyst Tim Mulrooney downgrades Kforce (NASDAQ:KFRC) from Outperform to Market Perform.
Coeptis Therapeutics Sets Sights on Expanding Cancer and Autoimmune Treatments in 2024
Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) (the "Company" or "Coeptis"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, today announced that Dave